| abstract |
The present invention provides a novel nitrosated and / or nitrosylated cyclooxygenase-2 (COX-2) selective inhibitor and at least one nitrosated and / or nitrosylated cyclooxygenase-2 (COX-2) selective inhibitor, At least one compound and / or any which is a substrate for nitric oxide synthase, which donates, transfers or releases nitric oxide at, stimulates endogenous synthesis of nitric oxide, increases endogenous levels of endothelium-derived relaxing factor A novel composition comprising at least one therapeutic agent. The present invention also includes a novel composition comprising at least one COX-2 selective inhibitor, optionally nitrosated and / or nitrosylated, and optionally at least one nitric oxide donor and / or at least one therapeutic agent. Offer things. The present invention also provides a method of treating inflammation, pain, and fever; a method of treating and / or improving the gastrointestinal properties of a COX-2 selective inhibitor; a method of promoting wound healing; the kidney and / or the respiratory tract Methods of treating and / or preventing toxicity; methods of treating and / or preventing other diseases caused by elevated cyclooxygenase-2 levels; and methods of improving the cardiovascular profile of COX-2 selective inhibitors . The invention also includes at least one COX-2 selective inhibitor, optionally at least nitrosated and / or nitrosylated, optionally at least one nitric oxide donor and / or optionally at least one therapeutic agent. Provide a new kit. The novel cyclooxygenase-2 selective inhibitor of the present invention is preferably 2 (2-((2-chloro-6-fluorophenyl) amino) 5-methylphenyl) acetic acid and its nitrosated derivatives. |